Thomas, Roman K. (2014). Overcoming Drug Resistance in ALK- Rearranged Lung Cancer. N. Engl. J. Med., 370 (13). S. 1250 - 1252. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Full text not available from this repository.Abstract
Approximately 4 to 15% of lung adenocarcinomas harbor a genomic rearrangement in the anaplastic lymphoma kinase gene (ALK) that creates a gene fusion activating the tyrosine kinase ALK.(1)-(4) Treatment of patients with ALK-rearranged lung cancer with the MET and ALK inhibitor crizotinib induces responses(5) and confers a benefit in progression-free survival.(6) In a nonrandomized registry study, crizotinib also improved overall survival.(4) Unfortunately, all patients who have ALK-rearranged lung cancer will have a relapse eventually, after a response that typically lasts for 8 months.(6) Thus, drugs that are capable of suppressing the growth of recurrent tumors ...
| Item Type: | Journal Article | ||||||||
| Creators: |
|
||||||||
| URN: | urn:nbn:de:hbz:38-443136 | ||||||||
| DOI: | 10.1056/NEJMe1316173 | ||||||||
| Journal or Publication Title: | N. Engl. J. Med. | ||||||||
| Volume: | 370 | ||||||||
| Number: | 13 | ||||||||
| Page Range: | S. 1250 - 1252 | ||||||||
| Date: | 2014 | ||||||||
| Publisher: | MASSACHUSETTS MEDICAL SOC | ||||||||
| Place of Publication: | WALTHAM | ||||||||
| ISSN: | 1533-4406 | ||||||||
| Language: | English | ||||||||
| Faculty: | Unspecified | ||||||||
| Divisions: | Unspecified | ||||||||
| Subjects: | no entry | ||||||||
| Uncontrolled Keywords: |
|
||||||||
| URI: | http://kups.ub.uni-koeln.de/id/eprint/44313 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
 |
View Item |